Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world
  • Posted by Suzan Serip, Artemis Rizoglou, Brett Gardiner
  • August 4, 2020
  • Articles

The race to secure a SARS-CoV-2 vaccine: big promises linked to big(ger) deals

The race to secure a SARS-CoV-2 vaccine: big promises linked to big(ger) deals

Market Access Director Brett Gardiner, Consultant Suzan Serip and Analyst Artemis Rizoglou explore the various SARS-CoV-2 vaccine supply deals that have been struck around the world.

As clinical trials for SARS-CoV-2 vaccines are still ongoing and final results are not expected until earlier than this autumn, in recent months we have witnessed an increasing amount of supply deals between governments and vaccine manufacturers.

read more »

  • Posted by George Forsyth
  • July 27, 2020
  • Articles

How will COVID-19 affect the financing of healthcare provision across the US?

How will COVID-19 affect the financing of healthcare provision across the US?

Using findings from our syndicated study to assess the impact of COVID-19 on biopharmaceutical market access, Senior Consultant George Forsyth explores the economic impact to the US healthcare system. Published by Pharma Exec in June 2020.

The current coronavirus pandemic sweeping across the globe represents one of the greatest fiscal challenges to US healthcare policymakers in modern times. The Federal Reserve expects the US economy to contract by a staggering 6.5% this year, with approximately 20 million Americans unemployed and many more without medical insurance. 

read more »

How we assessed the access potential of a new product in order to develop a successful launch strategy

How we assessed the access potential of a new product in order to develop a successful launch strategy

Our client had two regimens in clinical development for the front-line treatment of an oncology condition using a breakthrough product; and planned to release outcomes data at key industry events throughout the year.

To ensure a fast and successful launch they wanted to develop key strategies to maximise acceptance and reimbursement of their product amongst HCPs and Payers. 

read more »

  • Posted by Brett Gardiner, Rachel Howard & Suzan Serip
  • June 12, 2020
  • Articles

The unprecedented challenge of pricing a coronavirus vaccine

The unprecedented challenge of pricing a coronavirus vaccine

Using findings from our recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read our latest article for pharmaphorum.

The optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the eligible population in need across the world to gain access, while also rewarding innovation and supporting further research and development. The need for a SARS-CoV-2 vaccine is arguably more urgent, and more global, than ever before for a vaccine. As the 130+ vaccine candidates currently in development progress through clinical testing, a key question for their manufacturers is how COVID-19 might be changing the equation when it comes to what a responsible pricing strategy might look like. At the same time, payers are also faced with needing to prepare and plan for how to react and manage this situation.

read more »

  • Posted by Rachel Howard, Brett Gardiner & Richa Munjal
  • June 8, 2020
  • Articles

Breaking policy and perceptual barriers: Biosimilars

Breaking policy and perceptual barriers: Biosimilars

Our specialist market access and Therapy Watch teams analyse RA prescribing data to identify how market access policies across Europe may have impacted the adoption of biosimilars. Read our latest article for pharmaphorum's Deep Dive.

Biologics are big business in Rheumatoid Arthritis (RA), with the first wave of TNF inhibitors Remicade (infliximab), Enbrel (etanercept) and Humira (adalimumab) all having achieved blockbuster sales since their launches in the early 2000s. In recent years, as patents started to expire, an increasing number of branded and generic pharmaceutical companies have launched biosimilars, offering meaningful discounts relative to the originators – an appealing proposition for strained healthcare systems under pressure to contain costs. Leveraging over two years of syndicated RA Therapy Watch data* from September 2017-December 2019 in France, Germany, UK, Italy, and Spain, we looked into what parallels could be drawn between country trends in biosimilar prescribing and individual market policies designed to promote their use.

read more »